




Levetiracetam Granules for Oral Solution/Suspension – BP 2026

These chromatograms are provided for information only as an aid to analysts and are intended as guidance for the interpretation and application of BP monographs.

Typical chromatogram for solution (3) from the Related Substances test for Levetiracetam Granules for Oral Solution/Suspension as published in BP 2026.




Peak ID: 1: Levetiracetam. 2: Impurity A.

Column	Inertsil ODS3 C18 (250 mm x 4.6 mm, 5 µm)
Method Ref.	Related Substances for the Levetiracetam Granules for Oral Solution/Suspension monograph from BP 2026
Buffer (Solution A)	0.136% w/v potassium dihydrogen phosphate and 0.066% w/v sodium heptanesulfonate monohydrate, adjusted to pH 2.4 with orthophosphoric acid
Mobile Phase A	Acetonitrile: solution A (8:92, v/v)
Mobile Phase B	Acetonitrile
Diluent	Methanol

Flow rate	1.0 mL/min			
Column Temp	25°C			
Injection Volume	10 µL			
Detection	200 nm			
Gradient				
Time (minutes)	Mobile phase A (% v/v)	Mobile phase B (% v/v)	Flow rate (mL/min)	Comment
0 – 25	100	0	1.0	isocratic
25 – 45	100 → 52	0 → 48	1.0	linear gradient
45 – 47	52	48	1.0	isocratic
47 – 47.5	52 → 100	48 → 0	1.0	linear gradient
47.5 – 80	100	0	1.0	re-equilibration

Typical chromatogram for solution (3) from the Assay test for Levetiracetam Granules for Oral Solution/Suspension as published in BP 2026.



Peak ID: 1: Levetiracetam. 2: Impurity A.

Column	Inertsil ODS3-V (150 mm x 4.6 mm, 5 µm)
Method Ref.	Assay for the Levetiracetam Granules for Oral Solution/Suspension monograph from BP 2026
Mobile Phase	Acetonitrile: 0.02 M orthophosphoric acid (1:9, v/v)
Diluent	Mobile phase
Flow rate	1.0 mL/min
Column Temp	30°C
Injection Volume	10 µL
Detection	210 nm